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OBJECTIVE—Diabetic and prediabtic states, including insulin resistance, fasting hypergly-
cemia, and hyperinsulinemia, are associated with metabolic dysregulation. These components
have been individually linked to increased risks of cognitive decline and Alzheimer’s disease. We
aimed to comprehensively relate all of the components of metabolic dysregulation to cognitive
function and brain magnetic resonance imaging (MRI) in middle-aged adults.
RESEARCH DESIGN ANDMETHODS—Framingham Offspring participants who un-
derwent volumetric MRI and detailed cognitive testing and were free of clinical stroke and de-
mentia during examination 7 (1998–2001) constituted our study sample (n = 2,439; 1,311
women; age 61 6 9 years). We related diabetes, homeostasis model assessment of insulin re-
sistance (HOMA-IR), fasting insulin, and glycohemoglobin levels to cross-sectional MRI measures
of total cerebral brain volume (TCBV) and hippocampal volume and to verbal and visuospatial
memory and executive function. We serially adjusted for age, sex, and education alone (model
A), additionally for other vascular risk factors (model B), and finally, with the inclusion of
apolipoprotein E-´4, plasma homocysteine, C-reactive protein, and interleukin-6 (model C).
RESULTS—We observed an inverse association between all indices of metabolic dysfunction and
TCBV inallmodels (P,0.030). Theobserveddifference inTCBVbetweenparticipantswith andwithout
diabetes was equivalent to approximately 6 years of chronologic aging. Diabetes and elevated glycohe-
moglobin, HOMA-IR, and fasting insulin were related to poorer executive function scores (P, 0.038),
whereas only HOMA-IR and fasting insulin were inversely related to visuospatial memory (P, 0.007).
CONCLUSIONS—Metabolic dysregulation, especially insulin resistance, was associated
with lower brain volumes and executive function in a large, relatively healthy, middle-aged,
community-based cohort.
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A lzheimer’s disease (AD) afflicts asmany as 50% of people aged .85years and is associated with signifi-
cant health care and societal costs. With
the rapid aging of the U.S. population, it is
expected that, by the year 2050, the preva-
lence of AD will increase from the currently
estimated 5 million to.11 million afflicted
persons aged .65 years, unless effective
prevention or treatment is found (1).
Because late-onset AD is a slowly pro-
gressive disease that affects people aged
.65 years, some have argued that merely
delaying its onset by several years would
significantly decrease individual risk
and the population burden of disease.
The Framingham study estimated that a
5-year delay in the onset of AD would be
equivalent to a reduction of lifetime risk by
half, from 14 to 7% (2). Thus, although var-
ious disease-modifying agents are being
investigated, a parallel search for modifi-
able risk factors that could delay the onset
of AD would be a worthwhile endeavor.
Diabetes is a potentially modifiable
risk factor that has been related in several
population-based studies of older indi-
viduals to the risk of incident dementia
and AD (3). However, the argument that
it represents a causal factor would be
strengthened if similar associations were
demonstrable relating the entire spectrum
of prediabetic and diabetic states with
subclinical measures of subsequent AD
risk in younger persons aged ,65 years
who are, as yet, free of clinical disease. Fur-
thermore, examining insulin resistance
(IR), hyperinsulinemia, and hyperglyce-
mia, the three interwoven components of
the diabetic and prediabetic states, could
help clarify the relative importance of
these elements in determining the risk
of AD. To examine the possible associa-
tion of midlife diabetic and prediabetic
states with cognitive and brain magnetic
resonance imaging (MRI) markers of
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subsequent dementia and AD, we related
diabetes, glycohemoglobin A1c (HbA1c),
fasting serum insulin levels, and IR in the
middle-aged, cognitively intact Framingham
Offspring study population to measures
of structural and functional brain aging.
RESEARCH DESIGN AND
METHODS
Study population
The Framingham study’s original cohort
has been evaluated biennially since 1948
and screened prospectively for incident
dementia since 1978. A sample drawn
from the offspring (and spouses of the
offspring) of the original participants
(Framingham Offspring cohort) was en-
rolled in 1970–1972 and has been exam-
ined eight times during the past 37 years,
approximately once every 4 years. Partic-
ipants who attended offspring examina-
tion 7 (between 1998 and 2001) were
invited to participate in brain MRI studies
and a neuropsychologic assessment. The
study population comprised 2,439 indi-
viduals (1,311 women), with a mean age
of 626 9 years who agreed to participate
and were also free of clinical stroke, de-
mentia, or other neurologic conditions
such as a brain tumor that could alter
MRI and cognitive performance.
Brain MRI study
Image acquisition. The methods fol-
lowed for brain MRI have been described
previously (4). In brief, subjects underwent
neuroimaging on a Siemens Magnetom
(Munich, Germany) 1-T or 1.5-T field
strength machine using a double spin-
echo coronal imaging sequence of 4-mm
contiguous slices from nasion to occiput.
Imaging data were transferred to a central
location for processing and analyzed by
operators who were blinded to the sub-
ject’s identity, age, sex, exposure to stroke
risk factors, and cognitive performance on
neuropsychologic testing. Previously re-
ported semiautomated analyses of pixel
distributions based on mathematic mod-
eling of MRI pixel intensity histograms for
cerebrospinal fluid and white and gray
brain matter were used to determine the
optimal threshold of pixel intensity to best
distinguish cerebrospinal fluid from brain
matter (5). All analyses were performed
using QUANTA 6.2, a custom-designed
image analysis package, operating on an
Ultra 5 workstation (Sun Microsystems,
Santa Clara, CA).
Assessment of brain MRI measures.MRI
measures assessed consisted of total
cerebral brain volume (TCBV), hippocam-
pal volume (HV), and white matter hyper-
intensity volume. Brain volume was
determined bymanual outlining in coronal
images of the intracranial vault above the
tentorium to determine the total cranial
volume as a measure of head size. Once the
skull and other nonbrain tissues were re-
moved from the image, mathematic mod-
eling was performed to determine total
parenchymal brain volume above the
tentorium (cerebral). HV was estimated
using operator-defined, manually traced
boundaries. Because the medial wall of the
temporal horn consists of the hippocam-
pus, atrophy of the hippocampus will re-
sult in enlargement of the temporal horn
volume. White matter hyperintensity vol-
ume was measured according to previ-
ously published methods (6), expressed
as a proportion of the total intracranial vol-
ume, and log-transformed to normalize its
distribution. We estimated the equiva-
lency between the mean change in TCBV
associatedwith chronologic aging and that
associated with the presence of diabetes by
dividing the regression coefficient for diabe-
tes by the regression coefficient for age (7).
Cognitive evaluation
A comprehensive, well standardized, neu-
ropsychologic test battery was adminis-
tered to all participants and has been
described previously (8). The neuropsy-
chologic evaluation consisted of a 40-min
test battery that included tests of verbal
memory and abstract reasoning that were
previously associated with an increased
risk of developing AD in the original co-
hort (9). Also included were tests of
frontal executive function that are sensi-
tive in detecting cognitive impairment in
persons with diabetes (10). The cogni-
tive domains that we studied were verbal
memory (Wechsler Memory Scale–Logical
Memory), visual memory (Wechsler Mem-
ory Scale–Visual Reproduction), and exec-
utive function (Trail Making Tests A & B).
The MRI and neuropsychologic testing
were performed on the same day for most
participants and, in all cases, by evaluators
whowere blind to the diabetes,HbA1c, fast-
ing insulin, and IR data.
Diabetic and prediabetic states
Fasting glucose, HbA1c, and fasting insu-
lin levels were estimated from blood sam-
ples drawn at theOffspring examination 7
after participants had fasted overnight for
at least 8 h. Diabetes was determined by
use of insulin or other diabetes medica-
tion or a fasting glucose concentration
$126 mg/dL. Fasting glucose concentra-
tions were measured in fresh specimens
with a hexokinase reagent kit (A-gent
Glucose Test; Abbott Laboratories, Inc.,
South Pasadena, CA); the intra-assay co-
efficient of variation (CV) was ,3%.
HbA1c was measured using high-
performance liquid chromatography
(HPLC) assays standardized to Diabetes
Control and Complications Trial values by
theNationalGlycohemoglobin Standardiza-
tion Program (11). The HbA1c assays have
intra- and interassay CVs ,3%. Assay drift
in the HPLC method used in Framingham
Offspring Study is prevented by the use of
long-term stored reference samples.
Plasma insulin concentrations were
measured using the Coat-A-Count 125I–
labeled radioimmunoassay (Diagnostic
Products, Los Angeles, CA); this assay
has a cross-reactivity with proinsulin at
the midcurve of 40%; the intra- and inter-
assay CVs were 5 to 10%.
IR was estimated using a standardized
measure of insulin sensitivity: the homeo-
stasis model assessment of IR (HOMA-IR).
The HOMA-IR (mmol/L 3 mU/mL) for-
mula is defined as fasting insulin (mU/mL)
times fasting glucose (mmol/L)/22.5.
Statistical analyses
We related presence or absence of di-
abetes and levels of HbA1c, fasting insulin,
and HOMA-IR to the MRI and cognitive
outcomes listed in RESEARCH DESIGN AND
METHODS. Data for participants receiving
insulin treatment were excluded in the
analyses involving insulin levels.We con-
structed linear regression models ad-
justed for covariates previously shown to
affect brain volume and cognitive function
in the Framingham cohort including:
c Model A: age, sex, education (for cog-
nitive measures) only;
c Model B: the above with inclusion of
nondiabetes cardiovascular risk factors
at examination 7: systolic blood pres-
sure, smoking, prevalent cardiovascu-
lar disease;
c Model C: additional adjustment for
factors previously associated with risk
of dementia in the Framingham origi-
nal cohort, namely, apolipoprotein E
(apoE)-´4 genotype, and serum homo-
cysteine levels, C-reactive protein (CRP),
and interleukin-6 (IL-6) at examina-
tion 7.
We also adjusted for the time interval
between examination 7 and MRI or cog-
nitive testing in all analyses.
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In secondary analyses, we excluded
subjects with clinical diabetes and
looked at the effect of the duration of
diabetes on the relationship between
diabetes andMRI measures by stratifying
the subjects into three categories: 1)
nondiabetic as determined at Offspring
examination 7 and at the earlier exami-
nation 5 (1991–1995) using the same
criteria described earlier (referent); 2)
nondiabetic at examination 5 and dia-
betic at examination 7; 3) diabetic at ex-
aminations 5 and 7.
RESULTS—The characteristics of the
study population at examination 7 (1998–
2001) are presented in Table 1. We ob-
served an inverse association between all
indices (diabetes, HbA1c, HOMA-IR, fast-
ing insulin level) of metabolic dysfunction
evaluated at examination 7 and TCBV in
all models (Table 2). Adjustment for cova-
riates (models B and C; Table 2) did not
appreciably alter these associations. The
observed difference in TCBV of 1.24%
between participants with and without
diabetes was equivalent to the effect of
approximately 6 years of chronologic
aging. Of note, the association of IR and
hyperinsulinemia with TCBV remained
significant when the analysis was re-
stricted to subjects who had not yet de-
veloped clinical diabetes (Table 3). In
contrast, none of the metabolic indices
were associated with HV.
Considering the cognitive measures,
we found that examination 7 diabetes and
HbA1c, HOMA-IR and fasting insulin
were each related to poorer executive
function. This inverse relationship be-
tween executive function and HbA1c,
HOMA-IR, and fasting insulin persisted
even after adjustment for covariates (Ta-
ble 2) and the exclusion of participants
with clinical diabetes from the analysis
(Table 3). HOMA-IR and fasting insulin,
but not clinical diabetes or HbA1c, were
inversely related to visuospatial memory
(Table 2). These associations remained
significant after adjustment for covariates
(models B and C; Table 2).
A surprising finding was an apparent
association between diabetes and better
performance in verbal memory tasks, al-
though this effect was attenuated after
adjustment for all covariates. There was
an interaction with insulin levels, so that
this apparent beneficial effect was only
seen in subjects who also had elevated
plasma insulin levels and was not seen in
the subsample of participants who were
not receiving insulin.
Stratifying participants according to
their diabetes status at examination cycles
5 and 7 revealed that the cross-sectional
association between diabetes and TCBV
was present only in those participants who
had diabetes at both examination cycles
(diabetes duration $4 years; P , 0.001)
and not in those who developed diabetes
only at examination 7 (P = 0.113). No such
differential patterns according to length of
time with clinical diabetes were observed
for the other indices of metabolic dysfunc-
tion and measures of brain aging (Supple-
mentary Table 1A).
CONCLUSIONS—In the middle-aged
community sample of stroke- anddementia-
free Framingham Offspring participants,
we observed that clinical diabetes and
various metabolic indices associated with
diabetic and prediabetic states were asso-
ciated with the subclinical changes of
smaller brain volumes and poorer cogni-
tive performance, especially on tests of
executive function and visual memory.
These findings were observed even among
participants who did not have clinical di-
abetes, and the most consistent association
was with IR, which is important in the
evolution of clinical type 2 diabetes.
The relationship between diabetes
and cognition was reported .85 years
ago, when Miles and Root (12) observed
that patients with diabetes did not per-
form as well as control subjects in tests of
memory, mental arithmetic, and psy-
chomotor efficiency. Multiple studies
since then have shown an adverse effect
of baseline diabetes status on concomi-
tant cognitive function and cognitive de-
cline on follow-up. Diabetes has been
associated with cognitive changes that
affect learning and memory, mental
speed, and mental flexibility (13), and
population-based studies have also re-
lated diabetes to the risk of incident de-
mentia and AD (3). The Memory in
Diabetes (MIND) substudy of the Action
to Control Cardiovascular Risk in Diabe-
tes (ACCORD) trial showed an inverse
relationship between glycohemoglobin
levels and performance on cognitive tests;
whereas, fasting plasma glucose, a measure
with greater day-to-day variability, was
not associated with test performance (14).
The cognitive impairment associated with
diabetes may begin even before the appear-
ance of clinical disease; compared with
women with normal glucose, women
with impaired fasting glucose levels had
worse baseline cognitive scores and an al-
most twofold risk of developing cognitive
impairment over a 4-year period (15).
The pathophysiologic mechanisms
underlying the purported relationship
between diabetes, prediabetes, and demen-
tia, thus far, remains unclear but could in-
volve direct effects on AD neuropathology
or indirectly via diabetic vasculopathy,
leading to cerebrovascular brain injury.
Hyperglycemia can be harmful by pro-
moting oxidative stress, the formation of
toxic advanced glycation end products,
and induction for receptors for advanced
glycation end products. A direct effect of
insulin on cognition is supported by ob-
servations that insulin readily crosses the
Table 1—Characteristics of subjects at examination cycle 7 (1998–2001)
Characteristic Women Men
n 1,311 1,128
Age (years) 61 6 9 61 6 9
High-school degree 97.3 95.5
Current cigarette smoking 12.8 11.9
Systolic blood pressure 125 6 20 127 6 17
ApoE4 22.8 22.6
Plasma homocysteine (mmol/L) 7.7 6 2.5 9.1 6 4.1
CRP (mg/L) 4.5 6 5.4 3.7 6 6.8
IL-6 (pg/mL) 3.8 6 4.5 4.0 6 5.8
Diabetes 7.2 13.3
Fasting glucose (mg/dL) 99 6 22 108 6 29
HbA1c (%) 5.6 6 0.8 5.7 6 1.1
HOMA-IR (mmol/L 3 mU/mL) 3.9 6 3.7 5.0 6 4.2
Fasting insulin (mU/mL) 15.6 6 12.5 18.7 6 14.2
Time interval (years)
Examination 7 to MRI 0.8 6 0.8 0.8 6 0.9
Examination 7 to cognitive test 0.8 6 0.9 0.8 6 0.9
Continuous data are presented as mean 6 SD; categoric data as percentages.
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blood-brain barrier and the high concen-
tration of insulin receptors on the hippo-
campus and medial temporal cortex (16),
areas of the brain that are primarily in-
volved in memory and affected by AD
neuropathology. At excessively high or
low levels, insulin has been shown in
vitro to downregulate choline acetyl-
transferase (17), the enzyme that catalyzes
the production of the neurotransmitter
acetylcholine, which is deficient in AD.
Furthermore, insulin has been implicated
in t phosphorylation and amyloid depo-
sition, the pathophysiologic mechanisms
for AD (18).
Diabetes is an established risk factor
for stroke and other vascular disorders,
leading to an alternate hypothesis that the
link between diabetes and dementia is
indirect, mediated by vascular pathology
(19). In the Rotterdam Study, however,
diabetes was associated withMRImarkers
of AD risk, including smaller hippocam-
pus and amygdala volumes, even after ac-
counting for vascular pathology (20).
We found that, in this late adult
population with a mean age of 62 years,
clinical diabetes and each of the metabolic
dysfunction markers of IR, hyperinsu-
linemia, and hyperglycemia (elevated
HbA1c) were associated with signs of
accelerated brain aging, as measured by
MRI TCBV, and by poorer performance
on tests of executive function. The asso-
ciation with IR and hyperinsulinemia,
which are early markers of a compensated
prediabetic state, were also observed in a
subsample without clinical diabetes.
In addition, we found that there ap-
pear to be different patterns of associa-
tion between markers of a hyperglycemic
state versus measures of IR when each is
related to cognitive markers of aging.
Measures of IR (HOMA-IR and fasting
insulin levels) were inversely associated
with visual memory and executive func-
tion, whereas glycemic indices (diabetes
and HbA1c) were inversely associated only
with performance on executive function.
We also found a marginally significant
direct association between diabetes and
verbal memory, which disappeared after
adjusting for all covariates. This finding
is contrary to previously published studies
and may be a chance artifact given our co-
hort’s younger average age compared with
previous studies. Because it was restricted
to persons on insulin supplementation, it
could reflect a beneficial effect of exoge-
nous insulin on memory (21).
Our data strengthen earlier findings
relating diabetes status to cognitive
function, even in stroke- and dementia-
free community-dwelling middle-aged
men and women. Taken together, these
findings suggest that the insulin resistant
states seen in prediabetes and diabetes,
as well as hyperglycemia, accelerate brain
structural and cognitive aging, albeit in
slightly different patterns, with the most
robust associations being with IR.
In contrast to investigations into the
association between glycemia and cog-
nition, fewer studies have explored the
possible links between insulin levels and
Table 2—Association between metabolic dysregulation measures and markers of brain aging
Variable Model
HOMA-IR
(mmol/L 3 mU/mL) P
Fasting insulin
(mU/mL) P HbA1c (%) P Diabetes P
TCBV A 20.07 6 0.02 <0.001 20.02 6 0.01 <0.001 20.31 6 0.07 <0.001 21.24 6 0.20 <0.001
B 20.06 6 0.02 <0.001 20.02 6 0.01 <0.001 20.27 6 0.07 <0.001 21.08 6 0.20 <0.001
C 20.04 6 0.02 0.003 20.01 6 0.01 0.050 20.23 6 0.07 0.002 20.97 6 0.21 <0.001
HV A 20.000 6 0.000 0.428 20.000 6 0.000 0.731 20.001 6 0.001 0.476 20.003 6 0.004 0.380
B 20.000 6 0.000 0.461 20.000 6 0.000 0.746 20.001 6 0.001 0.510 20.003 6 0.004 0.436
C 20.000 6 0.000 0.521 20.000 6 0.000 0.891 20.001 6 0.001 0.423 20.003 6 0.004 0.522
Verbal memory A 0.007 6 0.006 0.287 0.001 6 0.002 0.781 0.02 6 0.02 0.406 0.15 6 0.07 0.031
B 0.007 6 0.006 0.295 0.001 6 0.002 0.744 0.02 6 0.02 0.515 0.14 6 0.07 0.039
C 0.005 6 0.007 0.503 20.000 6 0.002 0.808 0.02 6 0.02 0.495 0.14 6 0.07 0.059
Visual memory A 20.02 6 0.01 0.003 20.005 6 0.002 0.005 20.04 6 0.02 0.114 20.10 6 0.07 0.169
B 20.02 6 0.01 0.004 20.005 6 0.002 0.007 20.03 6 0.02 0.274 20.08 6 0.07 0.280
C 20.02 6 0.01 0.003 20.005 6 0.002 0.006 20.02 6 0.02 0.385 20.08 6 0.07 0.262
Executive function A 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.07 6 0.02 0.002 20.15 6 0.07 0.031
B 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.06 6 0.02 0.009 20.13 6 0.07 0.064
C 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.06 6 0.02 0.022 20.15 6 0.07 0.038
Model A: Adjusted for age, sex, education. Model B: Adjusted for age, sex, education, systolic blood pressure, smoking, history of cardiovascular disease. Model C:
Adjusted for age, sex, education, systolic blood pressure, smoking, history of cardiovascular disease, apoE-´4 genotype, serum homocysteine levels, CRP, IL-6.
Statistically significant relationships are in boldface.
Table 3—Association between metabolic dysregulation measures and markers of brain aging after exclusion of participants
with clinical diabetes*
Variable
HOMA-IR
(mmol/L 3 mU/mL) P
Fasting insulin
(mU/mL) P
HbA1c
(%) P
TCBV 20.10 6 0.03 ,0.001 20.03 6 0.01 ,0.001 0.02 6 0.12 0.859
HV 0.000 6 0.001 0.784 0.000 6 0.000 0.543 0.000 6 0.002 0.999
Verbal memory 0.008 6 0.009 0.405 0.001 6 0.002 0.574 20.035 6 0.043 0.404
Visual memory 20.011 6 0.009 0.193 20.004 6 0.002 0.132 0.000 6 0.043 1.000
Executive function 20.026 6 0.009 0.003 20.007 6 0.002 0.002 20.102 6 0.042 0.016
Values in boldface type are significant. *Adjusted for age, sex, and education (for cognitive measures).
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IR, and brain structure and cognitive per-
formance. Although hyperinsulinemia
has been directly linked (22) to AD risk,
there is also accumulating evidence link-
ing insulin levels and cognitive perfor-
mance in individuals without dementia.
Hyperinsulinemia has been associated
with lower scores on the Mini-Mental
State Examination in individuals without
dementia (23). Furthermore, IR, as mea-
sured by the HOMA-IR, has likewise been
associated with poorer cognition and,
more recently, with diffusely decreased
cortical glucose uptake on fluorodeoxy-
glucose-positron emission tomography
scans (24,25). Our findings of inverse re-
lationships between fasting insulin levels,
HOMA-IR, and brain volume and cogni-
tive performance—even after controlling
for vascular risk factors— appear to sup-
port these findings.
One limitation of our study is that we
only examined a cross-sectional associa-
tion but did not examine the association
of these measures with change. Another
limitation is the primarily white ethnicity
of the Framingham study sample; hence,
these associations need to be examined
among community-dwelling individuals of
other ethnicities. Our results do support
ongoing studies to examine whether early
detection and management of diabetes
and metabolic dysfunction, particularly IR,
would be able to delay the clinical onset of
cognitive disorders.
Diabetic and prediabetic states charac-
terized by IR, hyperinsulinemia, and hyper-
glycemia, when present in late middle age,
are related to decreased brain volume and
lower cognitive performance on executive
function and memory tasks. These results
extend the body of evidence linking meta-
bolic dysfunction to the risk of dementia
andAD in late life. These results suggest that
clinical trials attempting to delay cognitive
and structural brain loss by controlling
metabolic dysfunction, even in individuals
free of clinical diabetes and as early as the
7th decade, might be warranted.
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